Theseus Pharmaceuticals Cash Flow Statement

Financials in millions SAR. Fiscal year is January - December.

Millions SAR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	10.35	11.23	7.09
Depreciation & Amortization	7.33	6.87	6.72
Other Amortization	0.19	0.15	0.07
Loss (Gain) From Sale of Assets	-0.4	-	0.07
Loss (Gain) From Sale of Investments	-0.18	-0.18	-0.41
Other Operating Activities	2.4	1.92	2.26
Change in Inventory	-5.52	-4.18	-3.95
Change in Other Net Operating Assets	-0.6	-0.19	-3.02
Operating Cash Flow	12	15.63	8.84
Operating Cash Flow Growth	-	76.80%	-
Capital Expenditures	-2.26	-2.75	-3.87
Sale (Purchase) of Intangibles	-0.31	-0.29	-0.03
Investment in Securities	0.19	0.19	0.4
Investing Cash Flow	-2.38	-2.85	-3.5
Long-Term Debt Repaid	-	-6.36	-6.11
Net Debt Issued (Repaid)	-7.5	-6.36	-6.11
Financing Cash Flow	-7.5	-6.36	-6.11
Net Cash Flow	2.12	6.42	-0.77
Free Cash Flow	9.75	12.88	4.97
Free Cash Flow Growth	-	159.37%	-
Free Cash Flow Margin	14.68%	21.40%	10.04%
Free Cash Flow Per Share	4.87	6.44	2.48
Levered Free Cash Flow	-	7.1	-
Unlevered Free Cash Flow	-	7.82	-
Change in Net Working Capital	-	3.81	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.